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Context: Gestational diabetes mellitus (GDM)-associated hormonal and metabolic derangements
in mother and fetus affect placental development and function. Indeed, in GDM, placentas are
characterized by hypervascularization and vascular dysfunction. The membrane-type matrix met-
alloproteinase 1 (MT1-MMP) is a key player in angiogenesis and vascular expansion.
Objective: Here, we hypothesized elevated placental MT1-MMP levels in GDM induced by com-
ponents of the diabetic environment. Therefore, we measured placental MT1-MMP in normal vs.
GDM pregnancies, identified potential functional consequences, and investigated the contribu-
tion of hyperglycemia and the insulin/IGF axis.
Design: Immunohistochemistry identified placental cell types expressing MT1-MMP. MT1-MMP
was compared between normal and GDM placentas by immunoblotting. Quantitative PCR of
MT1-MMP in primary feto-placental endothelial cells (fpEC) and trophoblasts isolated from both
normal and GDM placentas identified the cells contributing to the GDM-associated changes. A
putative MT1-MMP role in angiogenesis was determined using blocking antibodies for in vitro
angiogenesis assays. PotentialGDM-associated factorsand signalingpathways inducingMT1-MMP
up-regulation in fpEC were identified using kinase inhibitors.
Results: Total and active MT1-MMP was increased in GDM placentas (51 and 54%, respectively,
P  0.05) as a result of up-regulated expression in fpEC (2.1-fold, P  0.02). MT1-MMP blocking
antibodies reduced in vitro angiogenesis up to 25% (P 0.03). Pathophysiological levels of insulin
and IGF-II, but not IGF-I and glucose, stimulated MT1-MMP expression in fpEC by phosphatidyl-
inositol 3-kinase signals relayed through the insulin, but not IGF-I, receptor.
Conclusions: GDM up-regulates MT1-MMP in the feto-placental endothelium, and insulin and
IGF-II contribute. This may account for GDM-associated changes in the feto-placental vasculature.
(J Clin Endocrinol Metab 97: 3613–3621, 2012)
Gestational diabetes mellitus (GDM) is an increasingproblem worldwide and affects about 4–15% of
pregnancies (1). GDM may compromise fetal develop-
ment in utero and also prime the offspring for an increased
risk of adult diseases (2). The placenta is a fetal organ
located between mother and fetus, supplies gases and nu-
trients to the fetus, and is exposed to both bloodstreams.
Thus, the placenta may be affected by GDM-associated
metabolic derangements in both the maternal and fetal
circulation, resulting in effects on placental morphology
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and function. Despite the profound increase of GDM and
the long-term consequences on the fetus, only little is
known about how GDM may affect placental structure.
Maternal hyperglycemia is the hallmark of GDM and
results also in fetal hyperglycemia, fetal hyperinsulinemia,
and other metabolic and hormonal changes in the fetal
circulation, such as elevated levels of IGF (3, 4). The ma-
ternal and the fetal circulations are in contact with two
different placental surfaces. The syncytiotrophoblast is
formed by fusion of cytotrophoblast cells, covers the pla-
cental villous structure, and is in contactwith thematernal
blood. The feto-placental vasculaturewithin the placental
villi is continuous with the fetal vasculature, lined by en-
dothelial cells, transports the fetal blood and hence is ex-
posed to endocrine and metabolic influences similar
to the vasculature of the fetus proper.
Therefore, diabetic derangements will primarily affect
these placental surfaces. Indeed, both surfaces are en-
larged. The syncytiotrophoblast surface is increased and
the villi are hypervascularized resulting in a larger feto-
placental endothelial surface. The feto-placental vascula-
ture is characterized by an increased diameter and hyper-
vascularization (5, 6), and signs of endothelial and
vascular dysfunction have been described (7).
The morphological and functional changes of the pla-
centa may contribute to the altered fetal development in
GDM. Short-term consequences of GDM for the fetus
may include excessive fat accretion (8). Recent data show
that the diabetic intrauterine environment in GDM can
program the fetus and determine the development of the
offspring into adulthood. Long-term consequences of
GDM include a higher risk for developing metabolic dis-
orders and vascular dysfunction (2). Genetic inheritance
of risk factors as well as fetal programming in utero con-
tribute to the increased risk (9).
The developmental processes of the placenta, i.e. an-
giogenesis and growth of the feto-placental vasculature as
well as invasion and fusion of the cytotrophoblast require
proper remodeling and breakdown of extracellular ma-
trix. Key molecules herein are matrix metalloproteinases
(MMP) (10). Dysregulation of some members of this pro-
tein family has been implicated in various pathologies as-
sociatedwith diabetes (11, 12), and hyperglycemia aswell
as insulin and IGF have been shown to regulate various
MMP (13, 14).
Feto-placental angiogenesis and vascular enlargement
as well as trophoblast fusion occur throughout pregnancy
until term (15). Therefore, these processesmay be affected
by the diabetic environment in GDM, which clinically
manifests as glucose intolerance in the second half of ges-
tation. However, studies demonstrate hormonal derange-
ments both in mother and fetus already in wk 11–15.
These changes include altered levels of insulin, IGF-I, and
leptin (16–18), indicating thatplacental developmentmay
already be affected by these hormonal changes before the
onset of GDM.
Membrane-type MMP1 (MT1-MMP) is a membrane-
anchored MMP and plays an outstanding role in struc-
tural remodeling. Established examples are angiogenesis
(19), tube formation (20), and arterial enlargement (21),
all of which are key features of endothelial cells. MT1-
MMP is synthesized as an inactive, 63-kDa pro-form,
transported to the cell membrane, and cleaved at a furin
recognition motif into the active 57-kDa enzyme. Apart
from the degradation of extracellular matrix components
such as collagens, fibronectin, laminin, and vitronectin
(22), MT1-MMP activates other MMP, i.e. MMP1,
MMP2, and MMP13. Moreover, it activates or inacti-
vates various cytokines and chemokines by cleaving their
pro-forms, e.g. pro-TGF- and pro-TNF-, or active
forms such as IL-8 and TNF- (23).
In this study, we tested the hypothesis that GDM is
associatedwith elevatedplacentalMT1-MMPlevels in the
third trimester. We localizedMT1-MMP-expressing cells
in the third-trimester placenta, identified the cells account-
ing forMT1-MMPexpression changes, and characterized
consequences of the stable alterations identified in GDM.
Moreover, we discovered components of the diabetic en-
vironment and signaling pathways by which they contrib-
ute to the MT1-MMP changes.
Subjects and Methods
Placenta samples
The studywas approvedby the institutional reviewboardand
ethical committee of the Medical University of Graz and of the
Medical Faculty, University of Milan. Informed consent of the
patients was obtained. After cesarean section, placentas were
collected after normal and GDM pregnancies and immediately
put on ice. A tissue sample of each placenta was taken within 3
cm of the cord insertion site of each placenta and snap frozen in
liquid nitrogen.
Subject characteristics
Control pregnancies (n14)were nonsmokingwomen,with
a negative 100-mg oral glucose tolerance test, free of medical or
obstetrical disorders. All neonates were delivered by elective ce-
sarean section and had a birthweight between the 10th and 90th
percentile.
GDMwas diagnosed at 28–32 wk of gestation with a 100-g
oral glucose tolerance test with two ormore values of the plasma
glucose exceeding the fasting value of 5.2mM, the 1-h value of 10
mM, the 2-h value of 8.6 mM, or the 3-h value 7.7 mM. After
diagnosis, all patients were followed according to a clinical pro-
tocol (24). The GDM women (n  9) monitored their capillary
glucose levels (memory reflectance meters, Accu-Chek; Roche
Diagnostics, Mannheim, Germany) at least four times a day.
3614 Hiden et al. GDM Elevates Feto-Placental Endothelial MT1-MMP J Clin Endocrinol Metab, October 2012, 97(10):3613–3621
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 14 January 2015. at 04:46 For personal use only. No other uses without permission. . All rights reserved.
They began appropriate diet providing 25–40 kcal/daykg ac-
cording to prepregnancy body mass index. Compliance was
checked bymeasuringmaternal glycemia and fetal growth every
2 wk. If maternal blood glucose values exceeded mean fasting
andpreprandial values of 5mMandpostprandial values of 6mM,
insulin therapywas instituted (n 2). All GDMpatients were in
goodmetabolic controlwithglycosylatedhemoglobinbelow5%
and achieved target preprandial below 5 mM and postprandial
below 6.6 mM glucose values until the last glucose control at the
day before delivery. None of the women showed signs of hyper-
tension or any other disease. The subject characteristics are
shown in Table 1.
Immunohistochemistry
Immunohistochemistry used the Ultra Vision LP detection
system (Thermo Scientific, Fremont, CA) with the horseradish
peroxidise polymer and the 3-amino-9-ethylcarbazole substrate
following manufacturer’s instructions. Tissue samples were
fixed in 4% paraformaldehyde and embedded in paraffin. Sec-
tions (5 m) were cleared with xylene, and rehydration was
followed by antigen retrieval with citrate buffer (pH 6.0). Sec-
tions were incubated with monoclonal mouse anti-MT1-MMP
(LEM-2/15.8; Millipore, Temecula, CA) in a concentration of 1
g/ml for 40 min at room temperature. Unspecific mouse IgG
(Dako, Glostrup. Denmark) was used as negative control. Sam-
ples were counterstained with hematoxylin and mounted with
Kaiser’s gelatin (Merck, Darmstadt, Germany).
Isolation of trophoblasts and feto-placental
endothelial cells (fpEC)
Primary trophoblasts and fpEC from third-trimester placen-
tas were isolated after uncomplicated vaginal delivery from nor-
mal and GDM pregnancies as described previously (25, 26).
Trophoblasts were cultured in DMEM (5.5 mM D-glucose;
Life Technologies, Inc., Paisley, UK) supplemented with 10%
fetal calf serum (FCS) and tested for viability bymeasuring-hu-
man chorionic gonadotropin levels secreted into the medium
(Dade Behring, Deerfield, IL). Purity was determined by immu-
nocytochemical staining for the trophoblast marker cytokeratin
7 (25). Only preparations with a purity of at least 99% and the
characteristic kinetics of human chorionic gonadotropin secre-
tion (27) were used. The fpEC were cultured on 1% (vol/vol)
gelatin-coated plates using endothelial basal medium (EBM,
Cambrex; Clonetics, Walkersville, MD) supplemented with
EGM-MV BulletKit (Clonetics). They were characterized by in-
ternalization of acetylated low-density lipoprotein and immu-
nohistochemical staining for the endothelial cellmarker vonWil-
lebrand factor and absent staining for fibroblast-specific antigen
and smoothmuscle actin (26). The fpECwere cultured and used
for experiments up to passage 5.
Oxygen is a key regulator of placental development particu-
larly in the first trimester of pregnancy. However, preliminary
experiments revealed no difference of MT1-MMP expression in
fpEC under different oxygen concentrations; thus, all experi-
ments were performed at ambient oxygen tension.
In vitro angiogenesis
In vitro network formationwas induced using growth factor-
reduced Matrigel basement membrane matrix (BD Biosciences,
Bedford, MA) as recommended by the manufacturer. Primary
fpEC were preincubated (30 min at 37 C) in EBM (2% FCS)
containing 15 g/ml nonspecific mouse IgG1 (BD PharMingen,
Bedford, MA) or 15 g/ml MT1-MMP blocking antibodies
(LEM-2/15.8 and LEM-2/63.1; Millipore). Then 8000 cells per
wellwere addedontopolymerizedMatrigel in 96-well plates and
incubated for 12 h at 37 C to allow for capillary-like network
development. Quantitative analysis measured the total tube
length and number of branching points of the network using
AngioJ-Matrigel assay plug-in (28), which was developed and
adapted for the ImageJ software (National Institutes of Health,
Bethesda, MD) by Dr. Diego Guidolin (University of Padova,
Padova, Italy). Each experiment was run in triplicate and inde-
pendently repeated four times with different cell isolations.
Immunoblotting
Tissue was homogenized and cells were washed and lysed in
buffer containing 10 mM Tris (pH 7.4), 1% sodium dodecyl
sulfate, 1 mM Na-orthovanadate, and Complete protease inhib-
itor (Roche) mixed with an equal volume of Laemmli sample
buffer (Sigma Chemical Co., St. Louis, MO). Before electropho-
resis, samples were centrifuged and boiled for 5 min at 99 C.
Equal amounts of proteinwere used for SDS-PAGEona10%gel
(Pierce, Rockford, IL). After electroblotting according to the
manufacturer’s instructions, membranes were stained with Pon-
ceauS to check for blotting efficiency and densitometrically
scanned.Then theywere blocked for 1hwith5%(wt/vol) nonfat
TABLE 1. Clinical characteristics of the study subjects
Control group (n  14) GDM group (n  9)
Mother
Age (yr) 34  5 37  3
Gestational age (wk) 38.7  0.7 38.6  0.4
Prepregnancy BMI 21.2  3.0 (18.7–27.3) 25.2  5.8 (17.1–32.5)
Postgravid BMI 26.1  4.1 (20.0–35.4) 29.7  7.3 (19.6–36.0)
Fasting blood glucose (mg/dl) (wk 36–40) Not determined 81.0  8.2
Postprandial blood glucose (mg/dl) (wk 36–40) Not determined 102.5  11.5
Treatment (n): diet/insulin 7/2
Fetus
Fetal weight (g) 3357  323 3320  456
Fetal height (cm) 51.5  1.4 50.2  0.8
Fetal ponderal index 24.6  2.4 26.2  3.6
Placental weight (g) 508  97 492  110
Values are presented as mean  SD. BMI, Body mass index.
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dry milk (Bio-Rad, Hercules, CA) and 0.1% (vol/vol) Tween 20
(Sigma) in 0.14 mol/liter Tris-buffered saline (pH 7.3) at room
temperature, which was also used for subsequent washings and
as an antibody diluent. The membranes were incubated over-
night at 4 C with polyclonal antibodies against MT1-MMP
(hinge region;Chemicon,Bedford,MA;0.5g/ml),-actin (Am-
ersham, Buckinghamshire, UK; 150 ng/ml), phospho-ERK1/
2Tyr202/204 (no. 9101; Cell Signaling, Danvers, MA; 1:1000), or
phospho-protein kinase B (PkB)Ser473 (no. 4050; Cell Signaling;
1:1000). After washing, membranes were incubated with the
secondary antibody (Bio-Rad; 1:1000) for 1 h at room temper-
ature. Immunolabeling was visualized using the SuperSignal
chemiluminescent substrate for horseradish peroxidise substrate
system (Pierce). Membranes were exposed to Hyperfilm (Amer-
sham) and densitometrically scanned using a digital camera and
the AlphaDigiDoc 1000 software within the linear range of film
and camera. Signals were normalized to -actin or to the total
protein amount in the respective molecular weight range of
MT1-MMP.
Real-time PCR
One microgram of total RNA isolated with TriReagent
(MRC, Cincinnati, OH) was reverse transcribed to cDNA
using SuperScript II reverse transcriptase (Invitrogen, Carls-
bad, CA) according to manufacturer’s instructions. cDNA
(100 ng) was subjected to real-time PCR using FAM-labeled
TaqMan gene expression assays (MMP14, Hs00237110_m1;
RPL30, Hs00265497_m1) and TaqMan Universal PCRMas-
termix (Applied Biosystems, Branchburg, NJ). Components
were mixed according to the manufacturer’s instructions and
amplified in 20 l total volume/well (96-well plates; Roche)
using an ABI7900 (Applied Biosystems) real-time cycler. Cy-
cle threshold (Ct) values were automatically generated by the
software (SDS version 2.2), and relative gene expression was
calculated by the standard 2Ct method (29) using gene
expression of ribosomal protein L30 (RPL30) as reference.
Statistical analyses used the Ct values.
Insulin/IGF and glucose treatment of fpEC
For the different treatments 40,000 cells per well were seeded
in gelatin-coated 24-well plates and cultured in EBM supple-
mented only with 2% (vol/vol) FCS. After 24 h, medium was
replacedby the samemediumsupplemented
with insulin (0.1 and 1 nM), IGF-I (6.7 and
13 nM), IGF-II (22 and 44 nM), or D-glucose
(17 and 25 mM). The basal glucose concen-
tration of EBMwas 5.5mM, and the insulin
concentration in EBM supplemented with
2% FCS was 0.002 nM. To identify recep-
tors and pathways involved, inhibitors for
the IGF-I receptor (IGF-IR) [picropodo-
phyllin (PPP), 100 nM], phosphatidylinosi-
tol 3-kinase (PI3K) (wortmannin; 100 nM),
or the ERK1/2 pathway (U0126; 10 M)
were added 1 h before treatment. IGF-I and
IGF-II were purchased from R&D Systems
(Minneapolis, MN) and insulin and the in-
hibitors from Calbiochem (Darmstadt,
Germany).
To confirm that the concentrations of
wortmannin and U0126 indeed blocked in-
sulin and IGF-II-induced phosphorylation
of PkB and ERK1/2, respectively, signaling experiments using
antibodies against phospho-ERK1/2Tyr202/204 and phospho-Pk-
BSer473 were performed. The fpEC were seeded as described
above, serum starved overnight, pretreated with wortmannin
(100 nM), U0126 (10 M), or dimethylsulfoxide (DMSO) alone
for 1 h, and stimulatedwith insulin or IGF-II (both 10 nM). After
15 min, cells were harvested and used for immunoblotting.
Data and statistical analysis
Fordata analysis, the immunoblots obtained fromthe insulin/
IGF and glucose treatment of fpEC were band intensity harmo-
nized for inter-blot variation. Each immunoblot replicate con-
tained the same sequence of untreated (control) and treated
(insulin, IGF-I, IGF-II, glucose, and inhibitor) samples, but from
different cell isolations. The average signal of each blot was ad-
justed to 100. This allowed calculation ofmean SD for controls
and treatments as well as statistical analysis.
Statistical analysis used Sigma Stat version 3.1 (Jandel Scien-
tific, San Rafael, CA) software. After testing for normal distri-
bution (Kolmogorov-Smirnov), Student’s t test was used. For
testing the effect of different insulin, IGF-I, and IGF-II concen-
trations, one-way ANOVA and Dunn’s method as post hoc test
was performed. For testing the effect of the inhibitors, two-way
ANOVA and Holm-Sidak post hoc test was used. Significances
were accepted at a level of P  0.05.
Results
Localization of MT1-MMP in the placenta in the
third trimester of gestation
Immunohistochemistrywas used to identify the cell types
expressing MT1-MMP in the normal third-trimester pla-
centa. The syncytiotrophoblast, subjacent cytotrophoblasts,
and the feto-placental endothelium showed intensive and
specificMT1-MMP staining (Fig. 1, A andB). Immunoblot-
ting revealed thatMT1-MMPprotein was also expressed in
primary trophoblasts and fpEC isolated from third trimester
placentaswith90%higher levels (P0.001) in fpEC(110
FIG. 1. Identification of placental cells expressing MT1-MMP in the normal third-trimester
placenta. Immunohistochemical staining of active MT1-MMP demonstrated high expression in
the syncytiotrophoblast and cytotrophoblasts and in the endothelium of the feto-placental
vessels (fV). A, overview of MT1-MMP staining in a placental villous cross-section with staining
in the syncytiotrophoblast (ST), the cytotrophoblast (CT), and the feto-placental endothelium
(E). Magnification, 200. The inset (a) shows the negative control using unspecific mouse
IgG. B, Higher magnification more clearly shows the staining of endothelial cells (400)
marked with an arrowhead. C, Quantification (immunoblotting) of MT1-MMP protein in
isolated trophoblasts (T) vs. isolated fpEC revealed expression in both cell types. D, One
representative immunoblot of five. Data are presented as mean  SEM.
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18 arbitrary units) compared with trophoblasts (58  28
arbitrary units) (Fig. 1, C and D).
MT1-MMP expression in normal and GDM
placentas
MT1-MMP protein is expressed in the third-trimester
placenta. Comparison of MT1-MMP in placentas from
GDM vs. normal pregnancies by immunoblotting re-
vealed about 50% higher levels (P 0.05) in total MT1-
MMP in GDM. When pro- (63 kDa) and active (57 kDa)
MT1-MMP were analyzed separately, only the approxi-
mately 55% increase in the active form was significant
(P  0.03) (Fig. 2, A and B).
MT1-MMP levels in fpEC and trophoblasts in
normal vs. GDM pregnancies
Furthermore, we aimed to identify whether tropho-
blasts, fpEC, or both account for the increased MT1-
MMP levels in GDM. Therefore, primary fpEC and tro-
phoblasts were isolated from normal and GDM
pregnancies, and their MT1-MMP expression was com-
pared using quantitative RT-PCR (Fig. 2C). The only sig-
nificant change was up-regulation ofMT1-MMP in fpEC
in association with GDM (fold change 2.1; P  0.02).
MT1-MMP function in in vitro angiogenesis of
fpEC
To identify potential consequences of the up-regulated
MT1-MMP in the feto-placental endothelium, we deter-
mined the role of MT1-MMP in fpEC. Angiogenesis as a
key process of endothelial cellswas chosen as an endpoint,
and in vitro angiogenesis assays were performed with and
without inhibition of MT1-MMP action. Because chem-
ical MMP inhibitors often interact also with other pro-
teases and are thus not absolutely specific, we used block-
ing antibodies. To increase credibility of the results, two
different clones of blocking antibodies were used. Unspe-
cific mouse IgG of the same isotype was added to the con-
trols. Addition of both MT1-MMP blocking antibodies
significantly reduced the total tube length by 20.0 and
22.5% (Fig. 3A) aswell as the number of branching points
by 21.0 and 24.8%, respectively (Fig. 3B).
Regulation of MT1-MMP expression in fpEC by
insulin, IGF-I, IGF-II, and glucose
We further aimed to identify potential factors of the
diabetic environment to account for MT1-MMP up-reg-
ulation in the feto-placental endothelium in the third tri-
mester. The concentrations of several metabolites are al-
tered in the fetal compartment resulting from maternal
GDM, e.g. glucose, amino acids, and nonesterified fatty
acids (24, 30, 31). In GDM, the fetus may be exposed to
hyperglycemia, which may result in a deregulation of the
insulin/IGF axis. High glucose as well as insulin/IGF are
known to alter, directly or indirectly, expression of
some MMP in different cell types (13, 14). Therefore,
fpECwere cultured in presence of insulin, IGF-I, IGF-II, or
glucose. Only the 57-kDa band of the active MT1-MMP
was detected when isolated cells were analyzed by immu-
noblotting. Insulin and IGF-II increased MT1-MMP ex-
pression in fpEC by 22  18 and 157  26%, whereas
IGF-I and glucose had no effect (Fig. 4, A and B). This
insulin and IGF-II effectwasblockedbypretreatmentwith
the PI3K inhibitor wortmannin but not by the ERK1/2
pathway inhibitor (U0126). Wortmannin indeed blocked
insulin- and IGF-II-stimulated phosphorylation of PkB at
FIG. 2. MT1-MMP expression in placental tissue and cultured
placental cells from normal and GDM pregnancies. MT1-MMP protein
was measured in third-trimester placental tissue from normal (n  14)
and GDM (n  9) pregnancies. Panel A, Representative immunoblot
for MT1-MMP and -actin. Panel B, Total (63 kDa) and active (57 kDa)
MT1-MMP are lower in control than in GDM placentas. Data are
presented as mean  SEM. Panel C, MT1-MMP mRNA expression in
fpEC and trophoblasts isolated from normal and GDM placentas as
determined by quantitative RT-PCR. Cells were isolated after normal
[control (C)] and GDM pregnancies. Trophoblasts were cultured for
48 h to allow them to regenerate after isolation. The fpEC were
cultured and expanded to passages 4–5 to obtain sufficient cells for
quality control and RNA isolation. Ribosomal protein L30 was used as
an internal control. Data are presented as mean of the fold changes 
SEM, and Ct values were used for statistical analysis. Sample size for
trophoblasts and fpEC is indicated in the bars.
J Clin Endocrinol Metab, October 2012, 97(10):3613–3621 jcem.endojournals.org 3617
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 14 January 2015. at 04:46 For personal use only. No other uses without permission. . All rights reserved.
Ser473,whereasU0126 fully abolished anyERK1/2 phos-
phorylation at Tyr202/204 (Fig. 4C). To identify which
receptor signals the IGF-II effect, the IGF-IR inhibitor PPP
was added. Currently, no inhibitor for the insulin receptor
is available. The blocking effect of PPP on IGF-IR signal-
ing was demonstrated by the inhibition of IGF-stimulated
in vitro angiogenesis of fpEC in presence of PPP (data not
shown). PPP did not abolish the IGF-
II-induced MT1-MMP up-regulation;
thus, the insulin receptor, but not the
IGF-IR, accounted for the IGF-II effect
(Fig. 4, D and E), which, like the insulin
effect itself, involves pathways down-
stream of PI3K.
Discussion
The present study reveals two major
findings. 1) GDM affects the fetal en-
vironment in such a way that MT1-
MMP, a key player in vascularization,
angiogenesis, and arterial enlargement,
is up-regulated. 2) MT1-MMP is ele-
vated only in the feto-placental endothelium, suggesting
the diabetic environment in the fetal rather than maternal
circulation induces its up-regulation.
One of the potential functions of MT1-MMP in endo-
thelial cells is its contribution to angiogenesis, which was
shown byMT1-MMPoverexpression in bovine aortic en-
FIG. 3. In vitro angiogenesis of primary fpEC in presence of MT1-MMP blocking antibodies.
In vitro angiogenesis was quantified by determining the total tube length (A) and the number
of branching points (B). Nonspecific mouse IgG1 was added to the controls in the same
concentration as the blocking antibodies LEM-2/15.8 and LEM-2/63.1 (15 g/ml). Data are
presented as mean  SEM of four independent experiments, each performed in triplicate.
FIG. 4. Effect of insulin and IGF on MT1-MMP expression in fpEC. The fpEC were isolated from normal third-trimester placentas treated for 48 h
with insulin, IGF-I, IGF-II, and D-glucose. Immunoblotting determined their effect on MT1-MMP protein levels. Because 2% FCS results in maximal
insulin and IGF levels of 2% of the physiological concentration, only the supplemented concentrations are indicated. A, Representative
immunoblot and PonceauS staining of the membrane. B, Data expressed relative to the controls. To identify signaling receptors and pathways
involved, cells were pretreated for 1 h with the PI3K inhibitor wortmannin, the ERK1/2 pathway inhibitor U0126, and the IGF-IR inhibitor PPP;
DMSO alone was added to the controls. Data are expressed relative to untreated controls (set to 100%). C, Representative immunoblots to test for
inhibitory effect of wortmannin (100 nM) on phosphorylation of PkB and U0126 on phosphorylation of ERK1/2 in isolated fpEC after insulin and
IGF-II treatment (both 10 nM) for 15 min. D, Representative immunoblot and PonceauS staining of the membrane. E, Data expressed relative to
DMSO-treated controls (set to 100%). Data are presented as mean  SEM; n  10. The statistical tests used the raw data. C, Control; D, DMSO; P,
PPP; U, U0126; W, Wortmannin.
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dothelial cells (32). Angiogenesis is a key function of fpEC
in the placenta throughout pregnancy (15) and might in-
volve MT1-MMP. This hypothesized role of MT1-MMP
in fpEC was indeed verified by reduced two-dimensional
network formation using MT1-MMP blocking antibod-
ies. In vitro angiogenesis is a useful tool to determine and
compare the effect of treatments on individual endothelial
cell isolations, inwhich theuntreated cells serve as internal
control. However, basal in vitro angiogenesis varies pro-
foundly between different cell isolations, thus precluding
its comparison between fpEC from normal vs. GDM
pregnancies.
The observed changes represent long-term effects of
maternal GDM on the feto-placental endothelial cells be-
cause changes were still present after five passages in cul-
ture. It was already shown that endothelial cells isolated
formdiabetic donors remember their endothelial dysfunc-
tion in culture (33). GDM can induce epigenetic changes
in various fetal organs (9), including the placenta (34).
However, whether this is the underlying cause for the sta-
ble up-regulation of MT1-MMP in fpEC isolated from
GDM pregnancies will be the focus of additional studies.
Because hyperglycemia and insulin/IGF regulate some
MMP(13, 14), the effect of hyperglycemia and the insulin/
IGF axis on MT1-MMP expression of fpEC in vitro was
determined. The insulin, IGF-I, and IGF-II concentrations
were chosen to mimic the physiological and pathological
concentrations of the growth factors in cord plasma of
normal and GDM pregnancies (3, 4). The glucose levels
chosen are commonly used for experiments mimicking
hyperglycemia (35). Both insulin and IGF-II stimulated
MT1-MMP production in endothelial cells. This effect
was dependent on the PI3K/PkB pathway. The IGF-IR
inhibitor PPP did not abolish the IGF-II effect. This
strongly suggests that the IGF-II signal is predominantly
relayed by the insulin receptor of which particularly the
isoform A (IR-A) is a signaling receptor for IGF-II (36).
The contribution of the IGF-IR, if any, will be rather mi-
nor, which is supported by an absentMT1-MMP increase
by IGF-I treatment, a growth factor that exclusively binds
to the IGF-IR (Fig. 5).The roleofPI3K/PkBsignaling in the
regulation of MT1-MMP expression is in line with data
from tumor cells, in which mammalian target of rapamy-
cinwas identified as a downstream link between PI3K and
MT1-MMP regulation (37).
The study is limited by the fact that tissues and cells
were obtained at the end of pregnancy, and any extrapo-
lations to earlier stages have to be made with caution. It
may well be that placental development is altered already
before GDM clinically manifests in the second half of ges-
tationbecause somemetabolic alterationsoccur already in
earlier phases of gestation as indicated by higher levels of
maternal glucose, insulin, and growth factors already in
the first trimester (17, 18). Furthermore, we previously
demonstrated that placental MT1-MMP is sensitive to-
ward the alterations of insulin and IGF-II levels in T1D
already during the first trimester (13). Because placental
vascularization is most pronounced in the third trimester
(15), it is likely to be sensitive to changes in the in utero
environment, whichwillmanifest as hypervascularization
found in all studies at the end of diabetic pregnancies.
Placental vascularization may thus be affected by the di-
abetic environment in the first and third trimester.
The study clearly shows that not only the GDM-asso-
ciated changes in the maternal environment but also the
resulting derangements in the fetal circulation can induce
modifications in theplacenta. Besides insulin and IGF-II as
identified here, other alterations including fetal hypoxia
and hyperleptinemia as well as elevated fetal fibroblast
growth factor 2 levelsmay contribute (38).On the basis of
the present data, it is tempting to speculate that theMT1-
MMP elevation in placental endothelial cells of GDM
pregnancies may lead to morphological and functional
changes also in the fetus vasculature. Hence, this study
fuels into the growing body of evidence that maternal di-
abetes contributes to fetal endothelial and vascular dys-
function. This notion is supported by studies using animal
models as well as human feto-placental and umbilical en-
dothelial cells and vessels (39, 40). Investigating these en-
dothelial and vascular changesmay help in understanding
the impact of diabetes on endothelial cell function.
FIG. 5. Signaling pathway by which insulin and IGF-II up-regulate
MT1-MMP expression in human placental endothelial cells. The IGF-IR
and the insulin receptor isoform A (IR-A) are the predominant signaling
receptors for IGF-II (36). Because the IGF-II effect was blocked by the
IGF-IR inhibitor PPP, the observed IGF-II effects are most likely mediated
by the insulin receptor isoform A. Up-regulation of MT1-MMP by both
insulin and IGF-II requires P13K signaling.
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